Seizure Drugs: Adult Efficacy Data May Be Extrapolated To Pediatric Patients
US FDA final guidance on partial onset seizure drugs reflects only one major change from an earlier draft version: the lowering of the youngest age for which extrapolation of efficacy is appropriate, from four years to two years.
You may also be interested in...
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
The first BCMA-targeting agent to gain approval in myeloma never became the blockbuster for which GSK had hoped, but Blenrep appears to have set a new standard for speed of voluntary withdrawal of an accelerated approval drug after a confirmatory trial failure.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.